Bernstein Maintains Outperform on Abbott Laboratories, Raises Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst Lee Hambright maintains an Outperform rating on Abbott Laboratories and raises the price target from $133 to $138.
October 17, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bernstein analyst Lee Hambright has reaffirmed an Outperform rating for Abbott Laboratories and increased the price target from $133 to $138, indicating a positive outlook.
The reaffirmation of an Outperform rating and the increase in price target from $133 to $138 by Bernstein suggests a positive sentiment towards Abbott Laboratories. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100